Cargando…
TM5441, a plasminogen activator inhibitor-1 inhibitor, protects against high fat diet-induced non-alcoholic fatty liver disease
Recent evidences showed that elevation of plasminogen activator inhibitor 1 (PAI-1) was responsible in mediating obesity-induced non-alcoholic fatty liver disease (NAFLD) and metabolic disorders. Here, we investigated the effect of TM5441, an oral PAI-1 inhibitor that lacks of bleeding risk, on high...
Autores principales: | Lee, Seon Myeong, Dorotea, Debra, Jung, Inji, Nakabayashi, Tetsuo, Miyata, Toshio, Ha, Hunjoo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685706/ https://www.ncbi.nlm.nih.gov/pubmed/29163785 http://dx.doi.org/10.18632/oncotarget.21120 |
Ejemplares similares
-
Novel Plasminogen Activator Inhibitor-1 Inhibitors Prevent Diabetic Kidney Injury in a Mouse Model
por: Jeong, Bo Yeong, et al.
Publicado: (2016) -
Peroxisomal Fitness: A Potential Protective Mechanism of Fenofibrate against High Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Mice
por: Jiang, Songling, et al.
Publicado: (2022) -
Deep molecular response in patients with chronic phase chronic myeloid leukemia treated with the plasminogen activator inhibitor‐1 inhibitor TM5614 combined with a tyrosine kinase inhibitor
por: Takahashi, Naoto, et al.
Publicado: (2022) -
Plasminogen Activator Inhibitor-1 Antagonist TM5484 Attenuates Demyelination and Axonal Degeneration in a Mice Model of Multiple Sclerosis
por: Pelisch, Nicolas, et al.
Publicado: (2015) -
Pan-Src kinase inhibitor treatment attenuates diabetic kidney injury via inhibition of Fyn kinase-mediated endoplasmic reticulum stress
por: Dorotea, Debra, et al.
Publicado: (2022)